These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 12491500)

  • 1. Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma.
    Diamanti-Kandarakis E; Sykiotis GP; Papavassiliou AG
    Cancer; 2003 Jan; 97(1):12-20. PubMed ID: 12491500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)].
    Tinelli A; Perrone A; Tinelli FG
    Minerva Ginecol; 2001 Apr; 53(2):127-35. PubMed ID: 11319506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulators and postmenopausal health.
    Roe EB; Chiu KM; Arnaud CD
    Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of selective estrogen receptor modulators.
    Krueger PM
    J Am Osteopath Assoc; 2000 Oct; 100(10 Su Pt 1):S6-8. PubMed ID: 11105457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective estrogen receptor modulators (SERMs) in the practice].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
    Saji S; Kuroi K
    Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Menopause and hormone replacement therapy].
    Tóth KS
    Orv Hetil; 2000 Mar; 141(11):547-56. PubMed ID: 10741167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal hormone replacement therapy: endometrial and breast effects.
    Yeh IT
    Adv Anat Pathol; 2007 Jan; 14(1):17-24. PubMed ID: 17198307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SERMs: progress and future perspectives.
    Pickar JH; MacNeil T; Ohleth K
    Maturitas; 2010 Oct; 67(2):129-38. PubMed ID: 20580502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K; Wycisk A
    Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
    Kastelan D; Korsić M
    Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF; Chlebowski RT
    Menopause; 2008; 15(4 Suppl):804-9. PubMed ID: 18596602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.